ECSP17069712A - Agente terapéutico para disfunción del lóbulo frontal - Google Patents
Agente terapéutico para disfunción del lóbulo frontalInfo
- Publication number
- ECSP17069712A ECSP17069712A ECIEPI201769712A ECPI201769712A ECSP17069712A EC SP17069712 A ECSP17069712 A EC SP17069712A EC IEPI201769712 A ECIEPI201769712 A EC IEPI201769712A EC PI201769712 A ECPI201769712 A EC PI201769712A EC SP17069712 A ECSP17069712 A EC SP17069712A
- Authority
- EC
- Ecuador
- Prior art keywords
- disease
- cognitive impairment
- lewy body
- frontal lobe
- therapeutic agent
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 210000001652 frontal lobe Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 4
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 4
- 208000010877 cognitive disease Diseases 0.000 abstract 4
- 201000002832 Lewy body dementia Diseases 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037326 chronic stress Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004558 lewy body Anatomy 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un agente terapéutico y/o preventivo, por ejemplo, para disfunción del lóbulo frontal (por ejemplo, alteración cognitiva (por ejemplo, alteración cognitiva en enfermedad de Parkinson, alteración cognitiva causada por estrés crónico, demencia con cuerpos de Lewy, parálisis supranuclear progresiva, demencia frontotemporal, y similares), y otros), enfermedad de cuerpos de Lewy (por ejemplo, alteración cognitiva en enfermedad de Parkinson, enfermedad difusa de cuerpos de Lewy, demencia con cuerpos de Lewy, trastorno del movimiento asociado con enfermedad de cuerpos de Lewy, y similares), y otros, que contiene un compuesto representado por la fórmula (I) o una de sus sales farmacéuticamente aceptables como un ingrediente activo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17069712A true ECSP17069712A (es) | 2018-02-28 |
Family
ID=56919157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201769712A ECSP17069712A (es) | 2015-03-19 | 2017-10-18 | Agente terapéutico para disfunción del lóbulo frontal |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20180042910A1 (es) |
| EP (1) | EP3270923B1 (es) |
| JP (1) | JP6869893B2 (es) |
| KR (1) | KR20170129764A (es) |
| CN (1) | CN107405341A (es) |
| AR (1) | AR103972A1 (es) |
| AU (1) | AU2016234211B2 (es) |
| BR (1) | BR112017018165A2 (es) |
| CA (1) | CA2978426A1 (es) |
| CL (1) | CL2017002351A1 (es) |
| CO (1) | CO2017008814A2 (es) |
| CR (1) | CR20170405A (es) |
| CY (1) | CY1124459T1 (es) |
| DK (1) | DK3270923T3 (es) |
| DO (1) | DOP2017000206A (es) |
| EA (1) | EA032511B1 (es) |
| EC (1) | ECSP17069712A (es) |
| ES (1) | ES2884846T3 (es) |
| GE (2) | GEAP201914604A (es) |
| HR (1) | HRP20211340T1 (es) |
| HU (1) | HUE055387T2 (es) |
| IL (1) | IL254196A0 (es) |
| JO (1) | JO3544B1 (es) |
| LT (1) | LT3270923T (es) |
| MX (1) | MX381277B (es) |
| MY (1) | MY196076A (es) |
| PE (1) | PE20171621A1 (es) |
| PL (1) | PL3270923T3 (es) |
| PT (1) | PT3270923T (es) |
| RS (1) | RS62311B1 (es) |
| SG (1) | SG11201707012YA (es) |
| SI (1) | SI3270923T1 (es) |
| SV (1) | SV2017005527A (es) |
| TN (1) | TN2017000369A1 (es) |
| TW (1) | TWI723012B (es) |
| UA (1) | UA123578C2 (es) |
| WO (1) | WO2016148308A1 (es) |
| ZA (1) | ZA201706136B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69834500T2 (de) | 1997-09-05 | 2007-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthinderivative zur behandlung von hirnischämie |
| JP4638355B2 (ja) * | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en not_active Ceased
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 GE GEAP201914604A patent/GEAP201914604A/en unknown
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Withdrawn
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja not_active Expired - Fee Related
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 MX MX2017012020A patent/MX381277B/es unknown
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
-
2017
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2021
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
| DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
| MX2018009861A (es) | Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
| CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| SV2016005305A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| ECSP17069712A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
| CO2020001792A2 (es) | Combinaciones farmacéuticas | |
| JP2018508540A5 (es) | ||
| MX2018000418A (es) | Derivados de amida que tienen actividad multimodal contra el dolor. | |
| JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll | |
| ITUB20153076A1 (it) | Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento. |